Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Ann Intern Med ; 135(6): 412-22, 2001 Sep 18.
Artigo em Inglês | MEDLINE | ID: mdl-11560454

RESUMO

BACKGROUND: Amphotericin B deoxycholate is currently the standard empirical antifungal therapy in neutropenic patients with cancer who have persistent fever that does not respond to antibiotic therapy. However, this treatment often causes infusion-related and metabolic toxicities, which may be dose limiting. OBJECTIVE: To compare the efficacy and safety of itraconazole with those of amphotericin B as empirical antifungal therapy. DESIGN: An open randomized, controlled, multicenter trial, powered for equivalence. SETTING: 60 oncology centers in 10 countries. PATIENTS: 384 neutropenic patients with cancer who had persistent fever that did not respond to antibiotic therapy. INTERVENTION: Intravenous amphotericin B or intravenous itraconazole followed by oral itraconazole solution. MEASUREMENTS: Defervescence, breakthrough fungal infection, drug-related adverse events, and death. RESULTS: For itraconazole and amphotericin B, the median duration of therapy was 8.5 and 7 days and the median time to defervescence was 7 and 6 days, respectively. The intention-to-treat efficacy analysis of data from 360 patients showed response rates of 47% and 38% for itraconazole and amphotericin B, respectively (difference, 9.0 percentage points [95% CI, -0.8 to 19.5 percentage points]). Fewer drug-related adverse events occurred in the itraconazole group than the amphotericin B group (5% vs. 54% of patients; P = 0.001), and the rate of withdrawal because of toxicity was significantly lower with itraconazole (19% vs. 38%; P = 0.001). Significantly more amphotericin B recipients had nephrotoxicity (P < 0.001). Breakthrough fungal infections (5 patients in each group) and mortality rates (19 deaths in the itraconazole group and 25 deaths in the amphotericin B group) were similar. Sixty-five patients switched to oral itraconazole solution after receiving the intravenous formulation for a median of 9 days. CONCLUSIONS: Itraconazole and amphotericin B have at least equivalent efficacy as empirical antifungal therapy in neutropenic patients with cancer. However, itraconazole is associated with significantly less toxicity.


Assuntos
Anfotericina B/administração & dosagem , Antifúngicos/administração & dosagem , Ácido Desoxicólico/administração & dosagem , Itraconazol/administração & dosagem , Micoses/tratamento farmacológico , Neoplasias/complicações , Neutropenia/imunologia , Infecções Oportunistas/tratamento farmacológico , Administração Oral , Anfotericina B/efeitos adversos , Antibacterianos/uso terapêutico , Antifúngicos/efeitos adversos , Antineoplásicos/efeitos adversos , Ácido Desoxicólico/efeitos adversos , Combinação de Medicamentos , Febre/etiologia , Humanos , Infusões Intravenosas , Itraconazol/efeitos adversos , Micoses/complicações , Neoplasias/tratamento farmacológico , Infecções Oportunistas/complicações , Fatores de Risco , Falha de Tratamento
3.
J Am Acad Dermatol ; 40(4): 635-6, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10188689

RESUMO

The development of lipodystrophy as evidenced by central obesity, "moon facies," and a "buffalo hump" is a classical feature of Cushing's disease. Recently an association of "lipodystrophy" with the use of protease inhibitors has been reported. We describe a patient with lipodystrophy secondary to protease inhibitor therapy for HIV infection.


Assuntos
Inibidores da Protease de HIV/efeitos adversos , Soropositividade para HIV/tratamento farmacológico , Indinavir/efeitos adversos , Lipodistrofia/induzido quimicamente , Feminino , Inibidores da Protease de HIV/uso terapêutico , Humanos , Indinavir/uso terapêutico , Lipodistrofia/diagnóstico , Pessoa de Meia-Idade , Pescoço
5.
Infect Control Hosp Epidemiol ; 17(11): 741-3, 1996 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8934242

RESUMO

An outbreak of Burkholderia cepacia lower respiratory tract colonization and infection occurred in the adult intensive-care units in various geographic locations throughout our hospital. Forty-four patients became colonized or infected over an 11-month period, whereas B cepacia had been isolated from only 13 patients in the preceding 48 months. Environmental cultures revealed the source to be extrinsically contaminated albuterol nebulization solution. Polymerase chain reaction-ribotyping confirmed the genetic relatedness of the B cepacia patient isolates and the contaminated albuterol. After extensive infection control training for the respiratory therapy staff, including attention to nebulization technique, washing and drying the nebulizer cup, and good handwashing, there have not been any new cases.


Assuntos
Albuterol , Infecções por Burkholderia/etiologia , Burkholderia cepacia , Infecção Hospitalar/etiologia , Surtos de Doenças , Contaminação de Medicamentos , Infecções Respiratórias/etiologia , Adulto , Humanos , Controle de Infecções , Unidades de Terapia Intensiva , Nebulizadores e Vaporizadores , Estudos Prospectivos , Estudos Retrospectivos
6.
Am J Ophthalmol ; 122(4): 584-6, 1996 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8862062

RESUMO

PURPOSE: To report the findings of Acanthamoeba endophthalmitis in a patient with acquired immunodeficiency syndrome (AIDS). METHODS: A 35-year-old man with AIDS and Acanthamoeba infection of the skin and lungs was treated for a granulomatous uveitis in the left eye. RESULTS: The left eye developed mutton-fat keratic precipitates, iris granulomas, cataract, hypotony, and choroidal infiltrates. Aqueous and vitreous specimens were positive for Acanthamoeba cysts. Topical and systemic antiamebic medications decreased the inflammation but failed to control the infection. CONCLUSIONS: Acanthamoeba infection should be considered in the differential diagnosis of uveitis in patients with AIDS.


Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Amebíase/complicações , Endoftalmite/complicações , Infecções Oculares Parasitárias/complicações , Acanthamoeba/isolamento & purificação , Adulto , Amebíase/tratamento farmacológico , Animais , Antiprotozoários/uso terapêutico , Humor Aquoso/parasitologia , Diagnóstico Diferencial , Endoftalmite/tratamento farmacológico , Endoftalmite/parasitologia , Infecções Oculares Parasitárias/tratamento farmacológico , Humanos , Pneumopatias Parasitárias/complicações , Pneumopatias Parasitárias/tratamento farmacológico , Masculino , Dermatopatias/complicações , Dermatopatias/tratamento farmacológico , Corpo Vítreo/parasitologia
7.
Clin Infect Dis ; 22(3): 462-6, 1996 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8852963

RESUMO

We undertook a retrospective review of all patients with hematologic malignancies in whom candidemia developed during chemotherapy-induced neutropenia in 1989 and 1990. Candidemia developed in 11 patients; five were receiving therapeutic doses of amphotericin B at the time of infection. Disseminated infection occurred in 2 of 5 patients with breakthrough infection and 3 of 6 patients with candidemia before receipt of amphotericin B. Among patients with breakthrough candidemia there was a trend toward more-prolonged neutropenia prior to infection (P = .069), but otherwise they were indistinguishable from other candidemic patients with regard to risk factors for candidemia. Amphotericin B-susceptible Candida albicans was isolated from two patients and Candida krusei from three patients with breakthrough infection. All patients were treated with amphotericin B; all breakthrough infections responded to treatment. Neutropenic patients with breakthrough candidemia were clinically similar to those whose candidemia preceded amphotericin B therapy, and there was no increase in morbidity and mortality among individuals with breakthrough infection.


Assuntos
Anfotericina B/uso terapêutico , Candida albicans/isolamento & purificação , Candida/isolamento & purificação , Candidíase/tratamento farmacológico , Leucemia Mieloide/complicações , Neutropenia/complicações , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Doença Aguda , Adulto , Idoso , Candida albicans/efeitos dos fármacos , Candidíase/complicações , Candidíase/parasitologia , Evolução Fatal , Feminino , Humanos , Leucemia Mieloide/parasitologia , Masculino , Pessoa de Meia-Idade , Neutropenia/parasitologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/parasitologia , Estudos Retrospectivos , Falha de Tratamento
8.
AJNR Am J Neuroradiol ; 17(1): 110-3, 1996 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-8770259

RESUMO

The case of a 55-year-old immunocompetent woman with central nervous system cryptococcosis and multiple intraventricular cysts is presented. The cysts did not enhance on MR and had signal characteristics similar to cerebrospinal fluid on T1- and T2-weighted images; their intensity was lower than cerebrospinal fluid on proton density-weighted images.


Assuntos
Ventrículos Cerebrais/patologia , Cistos/diagnóstico , Imageamento por Ressonância Magnética , Meningite Criptocócica/diagnóstico , Ventrículos Cerebrais/cirurgia , Líquido Cefalorraquidiano , Diagnóstico Diferencial , Feminino , Humanos , Hidrocefalia/diagnóstico , Meningite Criptocócica/cirurgia , Pessoa de Meia-Idade , Ventriculostomia
9.
J Clin Microbiol ; 32(11): 2635-40, 1994 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-7852548

RESUMO

In 1990, there was a significant increase in the number of lower respiratory tract infections and surgical wound infections in the adult intensive care units of our tertiary care teaching hospital caused by Acinetobacter baumannii compared with the number in 1989. During the 5-month period from April through August 1990, 84 isolates of A. baumannii were recovered from 50 hospitalized patients. Biotyping, comparison of antibiograms, plasmid analysis, and DNA polymorphisms of 20 isolates from 20 different patients, determined by the use of repetitive element PCR with primers aimed at repetitive extragenic palindromic sequences and enterobacterial repetitive intergenic consensus sequences, were used to investigate this apparent outbreak. Biotyping, antibiograms, plasmid analysis, and enterobacterial repetitive intergenic consensus PCR were not useful epidemiologically. Repetitive element PCR-mediated DNA fingerprinting using repetitive extragenic palindromic primers discriminated between epidemic and sporadic strains of A. baumannii and demonstrated four discrete clusters which were unique epidemiologically.


Assuntos
Acinetobacter/isolamento & purificação , Impressões Digitais de DNA , Reação em Cadeia da Polimerase , Acinetobacter/efeitos dos fármacos , Acinetobacter/genética , Sequência de Bases , Humanos , Testes de Sensibilidade Microbiana , Dados de Sequência Molecular , Plasmídeos
11.
Clin Infect Dis ; 17(4): 679-85, 1993 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-8268349

RESUMO

Implantable cardioverter defibrillators are being used with increasing frequency for the treatment of life-threatening ventricular arrhythmias. Nevertheless, no guidelines exist for the management of infections of these devices. We report our experience with infections of these devices and review the English-language literature. In all cases, patients presented with local signs of generator infection; systemic signs of infection and bacteremia were often absent. Most infections are due to staphylococcus. Risk factors for the development of infection include placement of the device via median sternotomy during another cardiac surgical procedure, reoperation, and intercurrent infection at another site. Infections are most reliably treated with full explantation of the device and antibiotics. In rare cases, patients may respond to a combination of intravenous antibiotics and removal and replacement of only the generator.


Assuntos
Desfibriladores Implantáveis/efeitos adversos , Infecção da Ferida Cirúrgica/terapia , Adulto , Idoso , Arritmias Cardíacas/terapia , Cefalosporinas/uso terapêutico , Ciprofloxacina/uso terapêutico , Escherichia coli/isolamento & purificação , Humanos , Masculino , Pessoa de Meia-Idade , Penicilinas/uso terapêutico , Estudos Retrospectivos , Fatores de Risco , Serratia marcescens/isolamento & purificação , Infecções Estafilocócicas/etiologia , Infecções Estafilocócicas/terapia , Staphylococcus aureus/isolamento & purificação , Streptococcus agalactiae/isolamento & purificação , Infecção da Ferida Cirúrgica/etiologia , Fibrilação Ventricular/terapia
12.
Antimicrob Agents Chemother ; 37(6): 1334-42, 1993 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8328783

RESUMO

Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen in hospitals. Current antimicrobial regimens for eradicating colonizing strains are not well defined and are often complicated by the emergence of resistance. The combination of novobiocin plus rifampin in vitro and in vivo was found to prevent the emergence of resistant populations of initially susceptible strains of MRSA, particularly resistance to rifampin. We therefore studied, in a randomized, double-blind, multicenter comparative trial, the combination of novobiocin plus rifampin versus trimethoprim-sulfamethoxazole (T/S) plus rifampin in order to determine the efficacy of each regimen in eradicating MRSA colonization and to further characterize the host factors involved in the response to this antimicrobial therapy. Among the 126 individuals enrolled in the study, 94 (80 patients; 14 hospital personnel) were evaluable. Among the 94 evaluable subjects, no significant demographic or medical differences existed between the two treatment groups. Successful clearance of the colonizing MRSA strains was achieved in 30 of 45 (67%) subjects receiving novobiocin plus rifampin, whereas successful clearance was achieved in 26 of 49 (53%) subjects treated with T/S plus rifampin (P = 0.18). The emergence of resistance to rifampin developed more frequently in 14% (7 of 49) of subjects treated with T/S plus rifampin than in 2% (1 of 45) of subjects treated with novobiocin plus rifampin (P = 0.04). Restriction endonuclease studies of large plasmid DNA demonstrated that the same strain was present at pretherapy and posttherapy in most refractory cases (24 of 29 [83%] subjects). Among the 56 successfully treated subjects, clearance of MRSA was age dependent: 29 of 36 (80%) subjects in the 18- to 49-year-old age group, 19 of 35 (54%) subjects in the 50- to 69-year-old age group, and 8 of 23 (35%) in the 70- to 94-year-old age group (P < 0.01). Clearance was also site dependent; culture-positive samples from wounds were related to a successful outcome in only 22 (48%) of 46 subjects, whereas culture-positive samples from sites other than wounds (e.g., nares, rectum, and sputum) were associated with a success rate of 34 of 48 (71%) subjects (P = 0.02). Foreign bodies in wounds did not prevent the eradication of MRSA by either regimen. T/S plus rifampin was less effective in clearing both pressure and other wounds, whereas novobiocin plus rifampin was equally effective in clearing both pressure and other wounds. There were no significant differences in toxicity between the two regimens. Thus, the combination of novobiocin plus rifampin, in comparison with T/S plus rifampin, was more effective in preventing the emergence of resistance to rifampin and demonstrated a trend toward greater activity in clearing the MRSA carrier state. The response to either combination depended on host factors, particularly age and the site of MRSA colonization.


Assuntos
Quimioterapia Combinada/uso terapêutico , Resistência a Meticilina , Infecções Estafilocócicas/tratamento farmacológico , Staphylococcus aureus , Infecção dos Ferimentos/tratamento farmacológico , Adolescente , Adulto , Idoso , DNA de Neoplasias/análise , Método Duplo-Cego , Quimioterapia Combinada/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Cavidade Nasal/microbiologia , Novobiocina/efeitos adversos , Novobiocina/uso terapêutico , Avaliação de Resultados em Cuidados de Saúde , Rifampina/uso terapêutico , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
13.
J Clin Microbiol ; 31(3): 518-23, 1993 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8458945

RESUMO

A dot immunobinding assay which uses a polyclonal rabbit anti-Candida immunoglobulin G as the primary antibody and colloidal gold coated with goat anti-rabbit immunoglobulin G as the secondary antibody for the detection of Candida cytoplasmic antigens is described. It was able to detect as little as 1 ng of total Candida protein per ml when a cytoplasmic extract of Candida albicans was seeded into buffer and 10 ng/ml when the same extract was seeded into pooled human serum. Serial serum samples from four groups of patients were assayed for Candida antigen: (i) 22 patients with candidemia, (ii) 16 patients at high risk for invasive candidiasis, (iii) 3 patients with other deep mycoses, and (iv) 50 hospitalized patients at low risk for serious Candida infection. Of the 22 candidemic patients, 19 had invasive candidiasis and 3 had transient candidemia. Antigenemia was detected in 16 of the 19 patients with invasive candidiasis (including patients with C. albicans, Candida tropicalis, Candida glabrata, Candida krusei, and Candida parapsilosis) and in 4 of 16 patients at high risk for invasive candidiasis. There was no detectable antigen in 12 high-risk control patients, 3 patients with transient candidemia, 3 patients with other deep mycoses, and 50 relatively low-risk patients. The sensitivity for detecting invasive disease in candidemic patients and specificity for all patients studied were 84.2 and 94.4%, respectively. The positive predictive value was 80%; the negative predictive value was 95.7%. The sensitivity for neutropenic patients with invasive disease was 85.7%. This assay is rapid and accurate and appears to be useful in identifying candidemic patients with invasive candidiasis.


Assuntos
Antígenos de Fungos/sangue , Candidíase/diagnóstico , Imunoensaio/métodos , Anticorpos Antifúngicos , Candida/classificação , Candida/crescimento & desenvolvimento , Ouro/imunologia , Humanos , Imunoglobulina G , Sensibilidade e Especificidade , Manejo de Espécimes
16.
Infect Control Hosp Epidemiol ; 11(6): 291-6, 1990 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-2373851

RESUMO

The reported prevalence of nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) by hospital personnel averages 2.5%. From August 1985 to September 1987, 155 patients at our Veterans' Affairs Medical Center (VAMC) were colonized or infected with MRSA. In December 1986, only two (2.1%) of 94 healthcare workers were identified as nasal carriers. Prompted by a sharp increase in the number of patients with MRSA in early 1987, contact tracing identified 450 employees, of whom 36 (8%) were nasal carriers. Thirty-five percent of surgical residents (7 of 20) were nasal carriers. Prior to being identified as a nasal carrier, one surgical resident was associated with the inter-hospital spread of the VAMC MRSA strain to the burn unit of the affiliated university hospital. Three family members of two employee carriers were also found to harbor the epidemic strain. All 36 carriers were decolonized with various antimicrobial combinations. Vigorous infection control measures were effective in controlling the epidemic. The frequency of MRSA carriage by hospital personnel at our medical center during the epidemic proved higher than previously appreciated. Thus, healthcare workers may comprise a sizable MRSA reservoir. During an MRSA epidemic, infection control should attempt to identify and decolonize this hospital reservoir, as these individuals can disseminate MRSA both within the hospital as well as into the community.


Assuntos
Infecção Hospitalar/epidemiologia , Surtos de Doenças , Meticilina/uso terapêutico , Resistência às Penicilinas , Infecções Estafilocócicas/epidemiologia , Infecção Hospitalar/tratamento farmacológico , Reservatórios de Doenças , Hospitais de Veteranos , Humanos , Recursos Humanos em Hospital , South Carolina , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/transmissão , Staphylococcus aureus/efeitos dos fármacos
17.
Pharmacotherapy ; 10(4): 301-4, 1990.
Artigo em Inglês | MEDLINE | ID: mdl-2117750

RESUMO

Infections in the cerebrospinal fluid (CSF) occur in an area of impaired host defenses; therefore, bactericidal antibiotics that reach adequate concentrations in the CSF are necessary for treatment. Measurements of antibiotic penetration into the CSF include CSF inhibitory and bactericidal titers, the absolute antibiotic concentration in the CSF, and the CSF: serum concentration ratio. We present the case of a patient with Listeria monocytogenes meningitis who failed to respond clinically to standard therapy, and whose organism demonstrated tolerance to Ampicillin (MBC: MIC = 258:1) that successfully responded to trimethoprim-sulfamethoxazole (TMP-SMX). The CSF peak bactericidal titer to TMP-SMX was 1:8, corresponding to that reported as necessary for successful outcome in patients with meningitis. The CSF peak: MBC ratios for TMP and SMX were less than 3:1 and equal to 3:1, respectively. These individual ratios are lower than those suggested for successful treatment of meningitis; however, the recommended ratios were established using single agents and did not account for synergistic activity with a drug combination such as TMP-SMX. The failure of standard therapy in this patient underscores the importance of MIC/MBC testing when tolerance is suspected or when CSF penetration of antibiotics is relatively poor. In addition, measurements of CSF inhibitory and bactericidal titers, which incorporate the antibiotic concentration in the CSF, susceptibility of the infecting microorganism, and host defense factors, may be useful in monitoring patients with meningitis.


Assuntos
Meningite por Listeria/tratamento farmacológico , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Adulto , Ampicilina/uso terapêutico , Resistência a Ampicilina , Gentamicinas/uso terapêutico , Humanos , Listeria monocytogenes/isolamento & purificação , Masculino , Meningite por Listeria/sangue , Meningite por Listeria/líquido cefalorraquidiano , Combinação Trimetoprima e Sulfametoxazol/sangue , Combinação Trimetoprima e Sulfametoxazol/líquido cefalorraquidiano
18.
Clin Microbiol Rev ; 2(4): 354-9, 1989 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-2680056

RESUMO

Erysipelothrix rhusiopathiae is a nonsporulating, gram-positive, rod-shaped bacterium which was identified more than 100 years ago as the etiologic agent of swine erysipelas. Since then, it has been found to cause infection in several dozen species of mammals and other animals. Humans become infected through exposure to infected or contaminated animals or animal products. By far the most common type of human infection is a localized, self-limited cutaneous lesion, erysipeloid. Diffuse cutaneous and systemic infections occur rarely. Approximately 50 cases of endocarditis have been reported; all but one recent case have involved native valves. The organism may be isolated from biopsy or blood specimens on standard culture media. It is identified by morphology, lack of motility, and biochemical characteristics; identification may be confirmed by the mouse protection test. It is susceptible to penicillins, cephalosporins, erythromycin, and clindamycin, but it is often resistant to many other antibiotics, including vancomycin, a drug frequently used in empiric therapy for infections due to gram-positive bacteria.


Assuntos
Erisipeloide , Erisipeloide/epidemiologia , Infecções por Erysipelothrix , Infecções por Erysipelothrix/epidemiologia , Erysipelothrix/crescimento & desenvolvimento , Animais , Erisipeloide/tratamento farmacológico , Erisipeloide/etiologia , Erisipeloide/patologia , Erysipelothrix/isolamento & purificação , Infecções por Erysipelothrix/tratamento farmacológico , Infecções por Erysipelothrix/etiologia , Infecções por Erysipelothrix/patologia , Humanos
19.
J Clin Microbiol ; 27(6): 1395-6, 1989 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-2754007

RESUMO

Of the 34 Bacillus species described, 10 have been reported to cause infection in humans and 6 are insect pathogens. We report a case of an infected prosthetic hip caused by Bacillus alvei, only the third documented case of human infection with this organism.


Assuntos
Artrite Infecciosa/etiologia , Bacillus , Prótese de Quadril , Osteíte/etiologia , Sepse/etiologia , Adulto , Artrite Infecciosa/tratamento farmacológico , Terapia Combinada , Desbridamento , Feminino , Articulação do Quadril/cirurgia , Humanos , Osteíte/tratamento farmacológico , Sepse/tratamento farmacológico
20.
Am J Dis Child ; 143(1): 34-9, 1989 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-2910044

RESUMO

Between October 1985 and August 1986, 49 isolates of methicillin-resistant Staphylococcus aureus (MRSA) were obtained from 26 neonates in the neonatal intensive care unit (NICU) at the Medical University Hospital, Charleston, SC. Sites of MRSA isolation were the respiratory tract (33%); nasopharynx (12%); gastrointestinal tract (12%); eye (8%); blood (6%); and catheter tips, wounds, or umbilicus (29%). Very low birth weight was a significant risk factor for MRSA acquisition. All isolates had the same phage type (47/54/75/83A), antibiogram, and whole-cell protein profile. Agarose gel electrophoresis of all 49 isolates disclosed a plasmid level of approximately 45 X 106 daltons (45 megadaltons) in ten different isolates and no plasmid DNA in 39 isolates. Cultures of NICU personnel failed to disclose MRSA carriers and environmental cultures for MRSA were negative. Ten selected isolates showed lower minimal bactericidal concentrations for hexachlorophene than for chlorhexidine. Standard infection-control measures such as contact isolation, hand washing with chlorhexidine, and cohorting (when possible) failed to contain the epidemic. Ultimately, eradication of MRSA from the NICU was associated with the institution of hexachlorophene hand washing.


Assuntos
Infecção Hospitalar/transmissão , Unidades de Terapia Intensiva Neonatal , Infecções Estafilocócicas/transmissão , Infecção Hospitalar/terapia , Resistência a Medicamentos , Gentamicinas/uso terapêutico , Hexaclorofeno , Humanos , Recém-Nascido de Baixo Peso , Recém-Nascido , Meticilina/uso terapêutico , Plasmídeos , Fatores de Risco , Infecções Estafilocócicas/terapia , Staphylococcus aureus/isolamento & purificação , Vancomicina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...